WHITEHAWK THERAPEUTICS, INC. Net Income (Loss) Available to Common Stockholders, Basic
WHITEHAWK THERAPEUTICS, INC. (WHWK) reported Net Income (Loss) Available to Common Stockholders, Basic of -$60.51 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-29.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2023-03-29
- WHITEHAWK THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2021-12-31 was -$15.99M.
- WHITEHAWK THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2021-09-30 was -$87.24M.
- WHITEHAWK THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2021-06-30 was -$4.41M, a 147.52% decline year-over-year.
- WHITEHAWK THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2021-03-31 was -$4.44M.
- WHITEHAWK THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2022 was -$60.51M.
- WHITEHAWK THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2021 was -$110.74M.
- WHITEHAWK THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2020 was -$4.32M.
- WHITEHAWK THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2019 was -$23.27M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$60.51M 10-K · filed 2023-03-29 | |||
| 2021-12-31 | -$15.99M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$103.23M derived: sum of 2 quarters · filed 2023-03-29 | -$107.64M derived: sum of 3 quarters · filed 2023-03-29 | -$110.74M 10-K · filed 2023-03-29 |
| 2021-09-30 | -$87.24M 10-Q · filed 2022-11-09 | -$91.65M derived: sum of 2 quarters · filed 2022-11-09 | -$94.75M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | -$4.41M 10-Q · filed 2021-08-11 | -$8.85M 10-Q · filed 2021-08-11 | ||
| 2021-03-31 | -$4.44M 10-Q · filed 2021-05-17 | |||
| 2020-12-31 | -$4.32M 10-K · filed 2021-03-11 | |||
| 2020-06-30 | $9.28M 10-Q · filed 2021-08-11 | $5.36M 10-Q · filed 2021-08-11 | $911.23K derived: sum of 3 quarters · filed 2021-08-11 | -$3.74M derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | -$3.92M 10-Q · filed 2021-05-17 | -$8.36M derived: sum of 2 quarters · filed 2021-05-17 | -$13.01M derived: sum of 3 quarters · filed 2021-05-17 | -$18.70M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | -$4.45M 10-K · filed 2020-03-16 | -$9.09M derived: sum of 2 quarters · filed 2020-03-16 | -$14.78M derived: sum of 3 quarters · filed 2020-03-16 | -$23.27M 10-K · filed 2021-03-11 |
| 2019-09-30 | -$4.65M 10-K · filed 2020-03-16 | -$10.33M derived: sum of 2 quarters · filed 2020-03-16 | -$18.82M 10-Q · filed 2019-11-07 | -$27.34M derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-06-30 | -$5.68M 10-K · filed 2020-03-16 | -$14.18M 10-Q · filed 2019-08-08 | -$22.70M derived: sum of 3 quarters · filed 2020-05-07 | -$11.16M derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-03-31 | -$8.49M 10-Q · filed 2020-05-07 | -$17.01M derived: sum of 2 quarters · filed 2020-05-07 | -$5.47M derived: sum of 3 quarters · filed 2020-05-07 | -$11.46M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | -$8.52M 10-K · filed 2020-03-16 | $3.02M derived: sum of 2 quarters · filed 2020-03-16 | -$2.97M derived: sum of 3 quarters · filed 2020-03-16 | -$10.40M 10-K · filed 2020-03-16 |
| 2018-09-30 | $11.54M 10-K · filed 2020-03-16 | $5.55M derived: sum of 2 quarters · filed 2020-03-16 | -$1.88M 10-Q · filed 2019-11-07 | -$8.11M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | -$5.99M 10-K · filed 2020-03-16 | -$13.42M 10-Q · filed 2019-08-08 | -$19.65M derived: sum of 3 quarters · filed 2020-03-16 | -$24.30M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-03-31 | -$7.43M 10-K · filed 2020-03-16 | -$13.66M derived: sum of 2 quarters · filed 2020-03-16 | -$18.31M derived: sum of 3 quarters · filed 2020-03-16 | -$23.83M derived: sum of 4 quarters · filed 2020-03-16 |
| 2017-12-31 | -$6.24M 10-K · filed 2019-03-07 | -$10.88M derived: sum of 2 quarters · filed 2019-03-07 | -$16.40M derived: sum of 3 quarters · filed 2019-03-07 | -$22.34M 10-K · filed 2019-03-07 |
| 2017-09-30 | -$4.65M 10-K · filed 2019-03-07 | -$10.17M derived: sum of 2 quarters · filed 2019-03-07 | -$16.11M 10-Q · filed 2018-11-07 | -$20.68M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | -$5.52M 10-K · filed 2019-03-07 | -$11.46M 10-Q · filed 2018-08-14 | -$16.03M derived: sum of 3 quarters · filed 2019-03-07 | -$21.97M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | -$5.94M 10-K · filed 2019-03-07 | -$10.51M derived: sum of 2 quarters · filed 2019-03-07 | -$16.45M derived: sum of 3 quarters · filed 2019-03-07 | -$21.64M derived: sum of 4 quarters · filed 2019-03-07 |
| 2016-12-31 | -$4.57M 10-K · filed 2018-03-15 | -$10.51M derived: sum of 2 quarters · filed 2018-03-15 | -$15.70M derived: sum of 3 quarters · filed 2018-03-15 | -$20.91M 10-K · filed 2018-03-15 |
| 2016-09-30 | -$5.94M 10-K · filed 2018-03-15 | -$11.13M derived: sum of 2 quarters · filed 2018-03-15 | -$16.34M 10-Q · filed 2017-11-13 | |
| 2016-06-30 | -$5.19M 10-K · filed 2018-03-15 | -$10.40M 10-Q · filed 2017-08-10 | ||
| 2016-03-31 | -$5.21M 10-K · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |